NEUMÜNSTER, Germany, July 19, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company inspiring and enabling the global community to live their best life, today announced that its medical cannabis division, Tilray Medical, has launched a new platform cannabis education, WeCare-MedicalCannabisdedicated to providing resources and educating healthcare professionals and patients about medical cannabis.
WeCare-MedicalCannabis provides science and research-based cannabis content tailored to healthcare professionals, caregivers and patients to help them make informed decisions about medicinal cannabis and help them along their journey to discover how medicinal cannabis can support daily well-being and health. Designed to serve as a comprehensive, one-stop resource for medical cannabis information, WeCare-MedicalCannabis is now available in Germany, France, the UK and Portugal.
Sascha Mielcarek, Managing Director of Tilray Europe, said: “As global pioneers in medical cannabis, we are aware of the lack of access to scientific training in medical cannabis. WeCare-MedicalCannabis was created to bridge this gap and help provide the resources to help patients, caregivers, and healthcare professionals with the information they need to make informed decisions about medical cannabis. As cannabis legalization continues to expand across Europe, Tilray Medical is committed to providing informed and reliable advice to those wishing to learn more about medical cannabis.
Tilray Medical continues to work with leading patient associations and physician societies, bringing value to those impacted by changes in the medical landscape and who are at the forefront of global health initiatives. By providing access to educational platforms such as WeCare-MedicalCannabis, Tilray Medical continues to open and expand its world of wellness.
For more information, please visit our global platforms at WeCare-MedicalCannabis Germany, WeCare-MedicalCannabis France, WeCare-MedicalCannabis UK, WeCare-MedicalCannabis Portugal.
About Tilray Medical
Tilray Medical is dedicated to improving the quality of life of patients around the world, transforming lives and promoting the dignity of patients in need through safe and reliable access to a global portfolio of brands of medicinal cannabis. Tilray went from being one of the first companies to become a licensed producer of medicinal cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and then in Germany. Today, Tilray Medical is one of the largest branded suppliers of medicinal cannabis to patients, physicians, hospitals, pharmacies, researchers and governments, in 20 countries and on five continents.
For more information about Tilray Medical, visit Tilray Medical Canada, Tilray Medical Australia-New Zealand, Tilray Medical Europe
About Tilray Brands, Inc.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and in Latin America that changes people‘s lives for the better – one person at a time. Tilray Brands fulfills this mission by inspiring and empowering the global community to live their best life and by providing access to products that meet the needs of their mind, body and soul while invoking The well-being. Patients and consumers trust Tilray Brands to deliver a cultured experience of health and well-being through differentiated, high-quality brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s unparalleled production platform supports over 20 brands in over 20 countries, including complete cannabis offerings, hemp edibles and craft drinks.
For more information on how we are opening up a world of wellness, visit www.tilray.com and follow @tilray.
Certain statements contained in this communication that are not historical facts constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended. , and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “anticipate”, “future”, “should”, “could”, “allow”, “potential”, “envisage”, “believe”, “anticipate”, “estimate, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative form of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, objectives, projections or assumptions have been used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, prospects, analyzes or current expectations regarding, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including through Tilray Medical. Many factors could cause actual results, performance or achievements to differ materially from any forward-looking statements, and other risks and uncertainties currently unknown to the Company or that the Company deems immaterial could also cause actual results or actual events that differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see Tilray’s most recently filed annual information sheet and Tilray’s annual report on Form 10-K (and other periodic reports filed with the SEC) of Tilray written with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, except as required by securities laws. applicable securities so require. .
For more information: